{'fraction_non_alphanumeric': 0.02131782945736434, 'fraction_numerical': 0.040697674418604654, 'mean_word_length': 5.011627906976744, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
β‐HUMAN CHORIONIC GONADOTROPHIN AND CARCINO‐EMBRYONIC ANTIGEN IN THE MANAGEMENT OF OVARIAN CARCINOMA

Measurements of HCG and carcino‐embryonic antigen (CEA) were made in 26 patients with ovarian cancer to evaluate these substances as tumour markers; 13·4 per cent of 194 CEA estimations and 14·6 per cent of 144 HCG estimations were abnormal. CEA values were abnormal in 9 out of 26 patients and HCG values in 13 out of 26 patients. The implications of these findings particularly the presence of HCG are discussed.